US healthcare investment firm TCGX has closed a $600 million fund dedicated to biotechnology companies based in Asia, extending its investment platform into a region where it sees a growing pipeline of drug-discovery businesses.
The firm said in an October 7 announcement that TCGX Asia Life Sciences Fund I was oversubscribed and backed by a group of international institutional investors. It did not identify the limited partners, disclose the fund’s original target, or provide a timetable for deploying the capital.
A dedicated vehicle for Asia
The new fund will invest across stages of company development in biotechnology businesses based in Asia. TCGX said it intends to work with companies developing differentiated medicines for patients globally, although the announcement did not name any portfolio companies, target ownership levels, or typical check sizes.
TCGX Asia Life Sciences Fund I will operate separately from the firm’s flagship funds, which focus on biotechnology companies in the United States and Europe. The firm said the strategies will maintain their own regional investment teams while drawing on its broader scientific and investment network.
The close also marks a physical expansion for TCGX. The firm is opening offices in Hong Kong and Shanghai, adding to its existing presence in Palo Alto, San Francisco, and New York City. TCGX linked the move to increased early-stage drug discovery activity in China and a broader rise in biotechnology company formation across Asia.
Chen Yu, TCGX’s founder and managing partner, said the region has become a more important source of globally competitive biotechnology innovation. Dandan Dong, managing partner of TCGX in Asia, said the firm is seeing growth in the quality of science, entrepreneurial talent, and company formation across the region’s biotechnology ecosystem. Those assessments are company views rather than independently measured market claims.
Fund adds to Asian life-sciences capital
The $600 million close gives TCGX a substantial pool of capital for a specialized strategy at a time when Asian cities are competing to attract biotechnology companies, research teams, and investors. The fund’s Hong Kong and Shanghai offices place its team near two important life-sciences and capital-market centers, while its mandate allows investment across Asia rather than in a single country.
The vehicle is TCGX’s first biotech fund focused on Asia and confirmed the $600 million in commitments. The publication also noted that the fund will invest across development stages and that TCGX will run it alongside, but separately from, its US- and Europe-focused flagship funds.
The announcement follows other efforts to connect capital with life-sciences research in Hong Kong and the surrounding region. In March 2025, the Hong Kong University of Science and Technology and Shanghai Industrial Investment announced a Hong Kong Biotechnology Fund targeting HK$600 million, with a mandate that included university-related ventures and wider healthcare innovation.
TCGX described the fund as oversubscribed but did not disclose how much demand exceeded its target or identify the institutions that committed capital. It also did not provide fee terms, fund duration, geographic allocation targets, or the share expected to go to China-based companies. The firm said its objective is to partner with biotechnology companies developing medicines for global markets while keeping the new vehicle distinct from its US and European funds.